ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Field of Research : Haematology
Research Topic : antibody microarray
Clear All
Filter by Field of Research
Haematology (13)
Biochemistry and Cell Biology (1)
Cell Development, Proliferation and Death (1)
Gene Expression (incl. Microarray and other genome-wide approaches) (1)
Filter by Socio-Economic Objective
Expanding Knowledge in the Biological Sciences (1)
Filter by Funding Provider
National Health and Medical Research Council (12)
Australian Research Council (1)
Filter by Status
Closed (13)
Filter by Scheme
NHMRC Project Grants (6)
Project Grants (2)
Development Grants (1)
Discovery Early Career Researcher Award (1)
NHMRC Postgraduate Scholarships (1)
Programs (1)
Research Fellowships (1)
Filter by Country
Australia (3)
Filter by Australian State/Territory
NSW (2)
ACT (1)
VIC (1)
  • Researchers (1)
  • Funded Activities (13)
  • Organisations (10)
  • Funded Activity

    Characterisation Of CBF Acute Myeloid Leukaemia By MicroRNA Profiling

    Funder
    National Health and Medical Research Council
    Funding Amount
    $118,956.00
    Summary
    Recent studies have demonstrated the existence of small pieces of previously undescribed genetic material, known as microRNAs (miRNAs), which are thought to have critical functions across various biological processes and regulatory pathways in cells. This project aims to examine the role of these miRNAs in the development of abnormal cellular proliferation that leads to leukaemia, by examining the expression of all known miRNAs in the abnormal cells of our patients with leukaemia.
    More information
    Funded Activity

    Proof-of-concept Studies For A Novel Anti-thrombotic Agent

    Funder
    National Health and Medical Research Council
    Funding Amount
    $632,352.00
    Summary
    Blood clots cause most heart attacks and strokes, and platelets are the blood cells that form these clots. Drugs that block platelet function, such as aspirin, are used to prevent heart attack and stroke but are frequently ineffective. Here, we will develop a new drug that prevents platelet incorporation into blood clots, that will be suitable for the prevention of heart attack and stroke in humans, and that may improve on existing therapies.
    More information
    Funded Activity

    A Study Of The Mechanism For The Reduction Of Platelets Caused By Drugs

    Funder
    National Health and Medical Research Council
    Funding Amount
    $96,925.00
    More information
    Funded Activity

    Heparin-induced Thrombocytopenia And Thrombosis: Better Understanding Of Pathogenesis And Improving Diagnosis And Treatment

    Funder
    National Health and Medical Research Council
    Funding Amount
    $653,137.00
    Summary
    Heparin, a widely used drug, can cause an adverse effect which results in a fall of the platelet count and the development of serious thrombosis. This drug complication is mediated by an immune mechanism. This proposal aims to provide a better understanding of the disease mechanism. It also aims to develop a new test that will improve the diagnosis, and to produce a novel drug that will effectively suppress the immune reaction and improve the treatment.
    More information
    Funded Activity

    To Study The Development Of Bone Marrow Stromal Cell Ty Pes, In Particular That Of Bone Cells

    Funder
    National Health and Medical Research Council
    Funding Amount
    $201,859.00
    More information
    Funded Activity

    A Product Of The Immune Response Which Activates Blood Clotting

    Funder
    National Health and Medical Research Council
    Funding Amount
    $685,417.00
    More information
    Funded Activity

    Development Of New Drugs To Treat Leukemia By Genetic E Ngineering

    Funder
    National Health and Medical Research Council
    Funding Amount
    $133,962.00
    More information
    Funded Activity

    Drug-induced Immune Thrombocytopenia: Understanding The Disease Mechanisms Is The Key To Better Treatment

    Funder
    National Health and Medical Research Council
    Funding Amount
    $509,550.00
    Summary
    Many very commonly used medications cause an allergic reaction in a small number of patients that receive them. The allergic reaction results in platelets being destroyed and puts the patients at risk of bleeding. The patient recovers slowly if the drug is stopped but there is no other treatment and no way to reverse the effect quickly if the patient starts to bleed. This project will try to understand the mechanism of the condition and test a potential treatment.
    More information
    Funded Activity

    The Translation Of Dendritic Cell Biology Into Clinical Practice

    Funder
    National Health and Medical Research Council
    Funding Amount
    $3,674,406.00
    Summary
    This Program combines world recognized expertise in the science of immunology and the blood system, with top Australian expertise in the practice of bone marrow transplantation and the treatment of hematological malignancies. Its vision is to study the biology of dendritic cells, which are the specialized white cells that initiate the immune response, and then, to apply this knowledge to the design and introduction of novel diagnostic and therapeutic immune strategies, to improve the survival of .... This Program combines world recognized expertise in the science of immunology and the blood system, with top Australian expertise in the practice of bone marrow transplantation and the treatment of hematological malignancies. Its vision is to study the biology of dendritic cells, which are the specialized white cells that initiate the immune response, and then, to apply this knowledge to the design and introduction of novel diagnostic and therapeutic immune strategies, to improve the survival of patients with leukaemia, lymphoma and multiple myeloma.
    Read more Read less
    More information
    Funded Activity

    CHARACTERISATION AND ANTIBODY-MEDIATED TARGETING OF A NOVEL SPECIFIC MARKER FOR T CELL ALL/LYMPHOBLASTIC LYMPHOMA

    Funder
    National Health and Medical Research Council
    Funding Amount
    $586,146.00
    Summary
    Improvements in treatment have seen some types of leukaemia (a cancer of white blood cells) being curable in up to 90% of patients with the disease; however, other types of leukaemia do not respond to these drugs and new approaches are needed. We have discovered that some leukaemia cells express a unique protein not made by any other cell type. This project will analyse how this aberrant protein is made and how this process contributes to the development of leukaemia. Also, since this protein is .... Improvements in treatment have seen some types of leukaemia (a cancer of white blood cells) being curable in up to 90% of patients with the disease; however, other types of leukaemia do not respond to these drugs and new approaches are needed. We have discovered that some leukaemia cells express a unique protein not made by any other cell type. This project will analyse how this aberrant protein is made and how this process contributes to the development of leukaemia. Also, since this protein is unique to the leukaemia cells, it offers the opportunity to develop magic bullets able to target specifically to the leukaemia cells and to kill them. This project aims to make one such drug and to conduct preliminary testing.
    Read more Read less
    More information

    Showing 1-10 of 13 Funded Activites

    • 1
    • 2
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback